Mitochondrial DNA Content, an Inaccurate Biomarker of Mitochondrial Alteration in Human Immunodeficiency Virus-Related Lipodystrophy

ABSTRACT Lipoatrophy is a prevalent side effect of antiretroviral treatment of human immunodeficiency virus (HIV) infection. Its mechanisms are still disputed but include mitochondrial toxicity and, in particular, mitochondrial DNA (mtDNA) depletion induced by nucleoside reverse transcriptase inhibitors. To obtain an integrated evaluation of the mitochondrial alteration in lipoatrophy, we investigated the DNA, RNA, and protein levels in 15 samples of abdominal subcutaneous adipose tissue from HIV-infected patients with peripheral lipoatrophy and compared the results with those for 15 samples from age- and body mass index-matched controls. The DNA and RNA analyses used PCR-based techniques, while proteins were quantified with enzyme-linked immunosorbent assay and measurement of activities with spectrophotometric assays. Depletion of mtDNA and mtDNA-encoded MT-CO2 mRNA was present, but normal levels of mtDNA-dependent activity (cytochrome c oxidase) and protein (MT-CO2p) showed that it was compensated for. An increase in nuclear-DNA-dependent mitochondrial activities (citrate synthase and malate dehydrogenase) and protein (COX4I1p), as well as transcriptional up-regulation of nuclear-DNA-encoded mitochondrial genes (COX4I1 and UCP2), demonstrated increased mitochondrial biogenesis. However, the expression of the known transcription factors of mitochondrial biogenesis (TFAM, NRF1, GABPA, PPARGC1A, PPARGC1B, and PPRC1) was normal or decreased. Increased amounts of activated caspase 3 and of DDIT3 mRNA showed the induction of apoptosis and oxidative stress, respectively. The mtDNA content did not correlate with any other mitochondrial parameter. In conclusion, mtDNA content does not appear to be an accurate biomarker of mitochondrial alteration in lipoatrophic adipose tissue. The preservation of mtDNA-dependent mitochondrial functions occurred despite severe mtDNA depletion. The presence of significant oxidative stress and apoptosis did not correlate with the mtDNA content.

[1]  S. Mallal,et al.  Complications Associated with Nrti Therapy: Update on Clinical Features and Possible Pathogenic Mechanisms , 2004, Antiviral therapy.

[2]  S. Dimauro,et al.  Differential diagnosis of fatal and benign cytochrome c oxidase‐deficient myopathies of infancy , 1991, Neurology.

[3]  H. Motoshima,et al.  The NAD(P)H Oxidase Homolog Nox4 Modulates Insulin-Stimulated Generation of H2O2 and Plays an Integral Role in Insulin Signal Transduction , 2004, Molecular and Cellular Biology.

[4]  D. Pessayre,et al.  High Doses of Stavudine Induce Fat Wasting and Mild Liver Damage without Impairing Mitochondrial Respiration in Mice , 2006, Antiviral therapy.

[5]  F. Gottrand,et al.  Clinical, biochemical and morphological features of hepatocerebral syndrome with mitochondrial DNA depletion due to deoxyguanosine kinase deficiency. , 2005, Journal of hepatology.

[6]  I. James,et al.  Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level , 2002, Antiviral therapy.

[7]  S. Serrano,et al.  Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy , 2002, Virchows Archiv.

[8]  S. Amselem,et al.  Mitochondrial DNA transfer RNA gene sequence variations in patients with mitochondrial disorders. , 2001, Brain : a journal of neurology.

[9]  F. Foury,et al.  In Vivo Functional Analysis of the Human Mitochondrial DNA Polymerase POLG Expressed in Cultured Human Cells* , 2000, The Journal of Biological Chemistry.

[10]  A. Hamsten,et al.  Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy , 2003, AIDS.

[11]  L. Galluzzi,et al.  Altered Mitochondrial Rna Production in Adipocytes from HIV-Infected Individuals with Lipodystrophy , 2005, Antiviral therapy.

[12]  T. D. Pugh,et al.  Mitochondrial DNA Mutations, Oxidative Stress, and Apoptosis in Mammalian Aging , 2005, Science.

[13]  S. Dimauro,et al.  Myoclonic epilepsy and ragged‐red fibers with cytochrome oxidase deficiency: Neuropathology, biochemistry, and molecular genetics , 1989, Annals of neurology.

[14]  N. Romero,et al.  Apoptosis in mitochondrial myopathies is linked to mitochondrial proliferation. , 2006, Brain : a journal of neurology.

[15]  J. Lambeth,et al.  The neutrophil NADPH oxidase. , 2002, Archives of biochemistry and biophysics.

[16]  I. James,et al.  Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6–12 months of commencing nucleoside reverse transcriptase inhibitor therapy , 2004, AIDS.

[17]  B. Day,et al.  Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective , 2003, Nature Reviews Drug Discovery.

[18]  S. Staszewski,et al.  Evidence of Nucleoside Analogue Reverse Transcriptase Inhibitor‐Associated Genetic and Structural Defects of Mitochondria in Adipose Tissue of HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[19]  W. Rozenbaum,et al.  Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance , 2002, The Lancet.

[20]  S. Mallal,et al.  The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome. , 2004, Journal of HIV therapy.

[21]  R. Scarpulla,et al.  Nuclear activators and coactivators in mammalian mitochondrial biogenesis. , 2002, Biochimica et biophysica acta.

[22]  J. Leszyk,et al.  Mitochondrial Biogenesis and Remodeling during Adipogenesis and in Response to the Insulin Sensitizer Rosiglitazone , 2003, Molecular and Cellular Biology.

[23]  S. Lewin,et al.  Exposure to Dideoxynucleosides Is Reflected in Lowered Mitochondrial DNA in Subcutaneous Fat , 2002, Journal of acquired immune deficiency syndromes.

[24]  D. Cooper,et al.  In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. , 2005, The Journal of infectious diseases.

[25]  W. Rozenbaum,et al.  Altered Fat Differentiation and Adipocytokine Expression are Inter-Related and Linked to Morphological Changes and Insulin Resistance in HIV-1-Infected Lipodystrophic Patients , 2003, Antiviral therapy.

[26]  P. Yeni,et al.  Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial , 2002, AIDS.

[27]  D. Kelly,et al.  PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. , 2006, The Journal of clinical investigation.

[28]  S. Mallal,et al.  Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy , 2003, AIDS.

[29]  T. Maisonobe,et al.  Mitochondrial Damage Associated With Long‐Term Antiretroviral Treatment: Associated Alteration or Causal Disorder? , 2002, Journal of acquired immune deficiency syndromes.

[30]  T. Bourgeron,et al.  Biochemical and molecular investigations in respiratory chain deficiencies. , 1994, Clinica chimica acta; international journal of clinical chemistry.

[31]  R. Schmidt,et al.  Relationship of Mitochondrial DNA Depletion and Respiratory Chain Activity in Preadipocytes treated with Nucleoside Reverse Transcriptase Inhibitors , 2007, Antiviral therapy.

[32]  B. Fromenty,et al.  Adipocytes Targets and Actors in the Pathogenesis of HIV-Associated Lipodystrophy and Metabolic Alterations , 2004, Antiviral therapy.

[33]  B. Shiramizu,et al.  Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy , 2001, AIDS.

[34]  Francesc Villarroya,et al.  Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. , 2005, Trends in pharmacological sciences.

[35]  Patrick F. Chinnery,et al.  Mitochondrial DNA polymerase-γ and human disease , 2006 .

[36]  X. Matías-Guiu,et al.  Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. , 1999, AIDS.

[37]  P. Reiss,et al.  Prevalence of Lipoatrophy and Mitochondrial DNA Content of Blood and Subcutaneous Fat in HIV-1-Infected Patients Randomly Allocated to Zidovudine- or Stavudine-Based Therapy , 2003, Antiviral therapy.

[38]  M. Lombès,et al.  Mitochondrial Toxicity of Indinavir, Stavudine and Zidovudine Involves Multiple Cellular Targets in white and brown adipocytes , 2007, Antiviral therapy.

[39]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[40]  N. Romero,et al.  Late‐onset mitochondrial DNA depletion: DNA copy number, multiple deletions, and compensation , 2001, Annals of neurology.

[41]  R. Garesse,et al.  Animal mitochondrial biogenesis and function: a regulatory cross-talk between two genomes. , 2001, Gene.

[42]  C. Hoppel,et al.  Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine , 2005, AIDS.

[43]  J. Capeau,et al.  Some HIV Antiretrovirals Increase Oxidative Stress and Alter Chemokine, Cytokine or Adiponectin Production in Human Adipocytes and Macrophages , 2007, Antiviral therapy.

[44]  S. Mallal,et al.  Mitochondrial Proliferation, Dna Depletion and Adipocyte Differentiation in Subcutaneous Adipose Tissue of HIV-Positive Haart Recipients , 2002, Antiviral therapy.

[45]  Ò. Miró,et al.  Upregulatory Mechanisms Compensate for Mitochondrial DNA Depletion in Asymptomatic Individuals Receiving Stavudine Plus Didanosine , 2004, Journal of acquired immune deficiency syndromes.

[46]  M. Ryan,et al.  A mitochondrial specific stress response in mammalian cells , 2002, The EMBO journal.

[47]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[48]  G. McComsey,et al.  Update on mitochondrial toxicity of antiretrovirals and its link to lipodystrophy. , 2002, AIDS reviews.

[49]  J. Martinou,et al.  Mitochondria as the central control point of apoptosis. , 2000, Trends in cell biology.